title: Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters.
abstract: Infection and inflammation induce alterations in hepatic synthesis and plasma concentrations of the acute phase proteins. Our results show that apolipoprotein (apo) J is a positive acute phase protein. Endotoxin (LPS), tumor necrosis factor (TNF), and interleukin (IL)-1 increased hepatic mRNA and serum protein levels of apo J in Syrian hamsters. Hepatic apo J mRNA levels increased 10- to 15-fold with doses of LPS from 0.1 to 100 micrograms/100 g body weight within 4 h and were elevated for > or = 24 h. Serum apo J concentrations were significantly increased by 16 h and further elevated to 3.3 times that of control, 24 h after LPS administration. Serum apo J was associated with high density lipoprotein and increased fivefold in this fraction, after LPS administration. Hepatic apo J mRNA levels increased 3.5- and 4.6-fold, with TNF and IL-1, respectively, and 8.2-fold with a combination of TNF and IL-1. Serum apo J concentrations were increased 2.3-fold by TNF, 79% by IL-1, and 2.9-fold with a combination of TNF and IL-1. These results demonstrate that apo J is a positive acute phase protein.
authors.affiliation: Department of Medicine, University of California San Francisco 94121.
authors.forename: I
authors.initials: I
authors.lastname: Hardardóttir
authors.forename: S T
authors.initials: ST
authors.lastname: Kunitake
authors.forename: A H
authors.initials: AH
authors.lastname: Moser
authors.forename: W T
authors.initials: WT
authors.lastname: Doerrler
authors.forename: J H
authors.initials: JH
authors.lastname: Rapp
authors.forename: C
authors.initials: C
authors.lastname: Grünfeld
authors.forename: K R
authors.initials: KR
authors.lastname: Feingold
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000906:Antibodies; D002784:Cholesterol / Q000097:blood; D051152:Clusterin; D006224:Cricetinae; D004731:Endotoxins / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects*; D006023:Glycoproteins / Q000032:analysis / Q000096:biosynthesis* / Q000097:blood*; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology*; D007700:Kinetics; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008074:Lipoproteins / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008647:Mesocricetus; D018832:Molecular Chaperones; D008969:Molecular Sequence Data; D009928:Organ Specificity; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology; D012333:RNA, Messenger / Q000096:biosynthesis*; D011994:Recombinant Proteins / Q000494:pharmacology; D014280:Triglycerides / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
chemical_list: D000906:Antibodies; C495242:CLU protein, human; D051152:Clusterin; D004731:Endotoxins; D006023:Glycoproteins; D007375:Interleukin-1; D008070:Lipopolysaccharides; D008074:Lipoproteins; D018832:Molecular Chaperones; D010455:Peptides; D012333:RNA, Messenger; D011994:Recombinant Proteins; D014280:Triglycerides; D014409:Tumor Necrosis Factor-alpha; D002784:Cholesterol